171 related articles for article (PubMed ID: 38359902)
1. A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.
Nagpal S; Png Yi Jie J; Malinovskaya J; Kovshova T; Jain P; Naik S; Khopade A; Bhowmick S; Shahi P; Chakra A; Bhokari A; Shah V; Gelperina S; Wacker MG
ACS Nano; 2024 Feb; 18(8):6162-6175. PubMed ID: 38359902
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
3. Influence of the method of preparation on the characteristics and performance of cholesterol-based polymeric nanoparticles for redox-triggered release of doxorubicin in tumor cells.
Gonzalez-Fajardo L; Ndaya D; Kasi RM; Lu X
Int J Pharm; 2019 Nov; 571():118701. PubMed ID: 31593806
[TBL] [Abstract][Full Text] [Related]
4. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
5. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome.
Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM
J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877
[TBL] [Abstract][Full Text] [Related]
6. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
[TBL] [Abstract][Full Text] [Related]
7. Injectable drug delivery systems of doxorubicin revisited: In vitro-in vivo relationships using human clinical data.
Modh H; Fang DJ; Ou YH; Yau JNN; Kovshova T; Nagpal S; Knoll J; Wallenwein CM; Maiti K; Bhowmick S; Gelperina S; Pastorin G; Wacker MG
Int J Pharm; 2021 Oct; 608():121073. PubMed ID: 34481887
[TBL] [Abstract][Full Text] [Related]
8. Rapid scale-up and production of active-loaded PEGylated liposomes.
Roces CB; Port EC; Daskalakis NN; Watts JA; Aylott JW; Halbert GW; Perrie Y
Int J Pharm; 2020 Aug; 586():119566. PubMed ID: 32622812
[TBL] [Abstract][Full Text] [Related]
9. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
[TBL] [Abstract][Full Text] [Related]
10. Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin.
Gan K; Li Z; Darli PM; Wong T; Modh H; Gottier P; Halbherr S; Wacker MG
Int J Pharm; 2024 Apr; 654():123942. PubMed ID: 38403086
[TBL] [Abstract][Full Text] [Related]
11. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
12. Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil
Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2018 Sep; 82(3):521-532. PubMed ID: 29995186
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
14. Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore.
Gawne P; Man F; Fonslet J; Radia R; Bordoloi J; Cleveland M; Jimenez-Royo P; Gabizon A; Blower PJ; Long N; de Rosales RTM
Dalton Trans; 2018 Jul; 47(28):9283-9293. PubMed ID: 29796500
[TBL] [Abstract][Full Text] [Related]
15. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
[TBL] [Abstract][Full Text] [Related]
16. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
[TBL] [Abstract][Full Text] [Related]
17. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
18. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.
Smith JA; Costales AB; Jaffari M; Urbauer DL; Frumovitz M; Kutac CK; Tran H; Coleman RL
J Oncol Pharm Pract; 2016 Aug; 22(4):599-604. PubMed ID: 26183293
[TBL] [Abstract][Full Text] [Related]
19. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
[TBL] [Abstract][Full Text] [Related]
20. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
